Literature DB >> 6268760

Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.

R H Perry, G J Dockray, R Dimaline, E K Perry, G Blessed, B E Tomlinson.   

Abstract

Vasoactive intestinal peptide (VIP) and cholecystokinin (CCK) have been measured, by radioimmunoassay, in cerebral cortex obtained at autopsy from patients without neurological or psychiatric disease and from patients with Alzheimer's disease, depression and schizophrenia. Sephadex gel filtration indicated that over 90% of the CCK immunoreactivity was associated with the octapeptide in extracted material from the different clinical groups investigated. There were no significant differences from the normal in the overall concentrations of either VIP or CCK in any of the psychiatric groups examined, although differences in Alzheimer's disease were apparent when cases were grouped according to postmortem delay.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268760     DOI: 10.1016/0022-510x(81)90123-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance.

Authors:  Alexandra Plagman; Siobhan Hoscheidt; Kelsey E McLimans; Brandon Klinedinst; Colleen Pappas; Vellareddy Anantharam; Anumantha Kanthasamy; Auriel A Willette
Journal:  Neurobiol Aging       Date:  2019-01-09       Impact factor: 4.673

2.  Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.

Authors:  A Ernst; H Cramer; D Strubel; F Kuntzmann; G A Schoenenberger
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

3.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 4.  Neuropeptides in dopamine-containing regions of the brain.

Authors:  A Albanese; M C Altavista
Journal:  Ital J Neurol Sci       Date:  1984-12

5.  Cholecystokinin octapeptide improves hippocampal glutamatergic synaptogenesis and postoperative cognition by inhibiting induction of A1 reactive astrocytes in aged mice.

Authors:  Lei Chen; Ning Yang; Yue Li; Yitong Li; Jingshu Hong; Qian Wang; Kaixi Liu; Dengyang Han; Yongzheng Han; Xinning Mi; Chengmei Shi; Ying Zhou; Zhengqian Li; Taotao Liu; Xiangyang Guo
Journal:  CNS Neurosci Ther       Date:  2021-08-17       Impact factor: 5.243

6.  Regional Homogeneity of Resting-State Brain Activity Suppresses the Effect of Dopamine-Related Genes on Sensory Processing Sensitivity.

Authors:  Chunhui Chen; Daiming Xiu; Chuansheng Chen; Robert Moyzis; Mingrui Xia; Yong He; Gui Xue; Jin Li; Qinghua He; Xuemei Lei; Yunxin Wang; Bin Liu; Wen Chen; Bi Zhu; Qi Dong
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.